According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

老虎证券2026/03/03 21:42

Show original

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

The results of this trial mark a significant advancement in the safety profile of Ketamir-2, paving the way for its subsequent clinical development. The company emphasized that this discovery is expected to drive further exploration of the drug in therapeutic applications.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

According to the latest documents disclosed by the U.S. Securities and Exchange Commission (SEC), Mira Pharma (stock code: MIRA) announced that its candidate drug Ketamir-2 did not observe clinically significant dissociative or psychosis-inducing side effects in Phase I clinical trials.

You may also like

Crypto prices